Nuvelo’s rNAPc2 Received USFDA Fast Track Designations as First- and Second-Line Treatment of Metastatic Colorectal Cancer
- for first-line treatment of metastatic colorectal cancer (mCRC) to improve progression-free survival and overall survival when added to Avastin®-containing 5-flurourocil (5-FU)-based chemotherapy regimens
- for second-line treatment of mCRC to improve progression-free survival and overall survival when added to 5-FU-based chemotherapy regimens
A USFDA Fast track designation is reserved for new drugs that demonstrate the potential to address an unmet medical need and are intended for the treatment of a serious or life-threatening condition.
Recombinant nematode anticoagulant protein c2 (rNAPc2), a recombinant protein that interferes with the tissue factor/factor VIIa/factor Xa protease complex is currently under phase II clinical trial.
The tissue factor/factor VIIa/factor Xa protease complex has been found to play a role in activating the cellular signaling events leading to metastasis and angiogenesis in various cancers.
Find more details from the full report.
Comment Preview